Eyenovia to present at the Ophthalmology Innovation Summit (OIS) Presbyopia Innovation Showcase
NewsEyenovia to present at the Ophthalmology Innovation Summit (OIS) Presbyopia Innovation Showcase
NEW YORK--(BUSINESS WIRE)--Jan. 26, 2021-- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing…
Eyenovia Announces First Patients Enrolled in Phase 3 Study of MicroLine for Presbyopia
News
Eyenovia Announces First Patients Enrolled in Phase 3 Study of MicroLine for Presbyopia
Eyenovia Announces First Patients Enrolled in Phase 3 Study of MicroLine for Presbyopia Topline Results Expected First Half of 2021 December 16, 2020…
Eyenovia Submits New Drug Application to FDA for Pharmacologic Mydriasis
News
Eyenovia Submits New Drug Application to FDA for Pharmacologic Mydriasis with MydCombi Targeting 80 Million Patient Encounters in the U.S. Annually
December 29, 2020 07:00 AM Eastern Standard Time
NEW YORK--(BUSINESS WIRE)--Eyenovia,…
Eyenovia To Report Third Quarter 2020 Results
NewsNEW YORK, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc., (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that the Company will…